Benzinga | Nov 18, 2020 07:02AM EST

BioLineRx Announces Initiation Of Phase 1b Clinical Trial In Patients With Acute Respiratory Distress Syndrome Secondary To COVID-19 And Other Respiratory Viral Infections

TEL AVIV, Israel, Nov. 18, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be evaluated in an investigator-initiated clinical trial in patients suffering from acute respiratory distress syndrome (ARDS) secondary to COVID-19 and other respiratory viral infections.



The open-label, single-arm, Phase 1b study will be conducted at the Wolfson Medical Center in Holon, Israel, with Dr. Yasmin Maor, Head of the Infectious Disease Unit, as lead investigator.